A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
06
08
2020
accepted:
19
10
2020
revised:
14
10
2020
pubmed:
22
11
2020
medline:
2
2
2022
entrez:
21
11
2020
Statut:
ppublish
Résumé
Multiparametric magnetic resonance imaging (mpMRI), the use of three multiple imaging sequences, typically T2-weighted, diffusion weighted (DWI) and dynamic contrast enhanced (DCE) images, has a high sensitivity and specificity for detecting significant cancer. Current guidance now recommends its use prior to biopsy. However, the impact of DCE is currently under debate regarding test accuracy. Biparametric MRI (bpMRI), using only T2 and DWI has been proposed as a viable alternative. We conducted a contemporary systematic review and meta-analysis to further examine the diagnostic performance of bpMRI in the diagnosis of any and clinically significant prostate cancer. A systematic review of the literature from 01/01/2017 to 06/07/2019 was performed by two independent reviewers using predefined search criteria. The index test was biparametric MRI and the reference standard whole-mount prostatectomy or prostate biopsy. Quality of included studies was assessed by the QUADAS-2 tool. Statistical analysis included pooled diagnostic performance (sensitivity; specificity; AUC), meta-regression of possible covariates and head-to-head comparisons of bpMRI and mpMRI where both were performed in the same study. Forty-four articles were included in the analysis. The pooled sensitivity for any cancer detection was 0.84 (95% CI, 0.80-0.88), specificity 0.75 (95% CI, 0.68-0.81) for bpMRI. The summary ROC curve yielded a high AUC value (AUC = 0.86). The pooled sensitivity for clinically significant prostate cancer was 0.87 (95% CI, 0.78-0.93), specificity 0.72 (95% CI, 0.56-0.84) and the AUC value was 0.87. Meta-regression analysis revealed no difference in the pooled diagnostic estimates between bpMRI and mpMRI. This meta-analysis on contemporary studies shows that bpMRI offers comparable test accuracies to mpMRI in detecting prostate cancer. These data are broadly supportive of the bpMRI approach but heterogeneity does not allow definitive recommendations to be made. There is a need for prospective multicentre studies of bpMRI in biopsy naïve men.
Identifiants
pubmed: 33219368
doi: 10.1038/s41391-020-00298-w
pii: 10.1038/s41391-020-00298-w
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
596-611Subventions
Organisme : Wellcome Trust
ID : 204998/Z/16/Z
Pays : United Kingdom
Informations de copyright
© 2020. Crown.
Références
Ahmed HU, EL-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.
pubmed: 28110982
doi: 10.1016/S0140-6736(16)32401-1
Gandaglia G, Briganti A, Fossati N, Salonia A, Mottrie A, Catto J, et al. The problem is not what to do with indolent and harmless prostate cancer—the problem is how to avoid finding these cancers. Eur Urol. 2016;70:547–8.
pubmed: 26916048
doi: 10.1016/j.eururo.2016.02.032
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–90.
pubmed: 12096083
doi: 10.1093/jnci/94.13.981
Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.
pubmed: 25656808
doi: 10.1016/j.eururo.2015.01.013
Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH. Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis. Am J Roentgenol. 2018;211:W226–41.
doi: 10.2214/AJR.18.19880
Drost FH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. Eur Urol. 2020;77:78–94.
pubmed: 31326219
doi: 10.1016/j.eururo.2019.06.023
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, NICE guideline [NG131]. 2019. https://www.nice.org.uk/guidance/ng131 . Accessed 6 May 2020.
European Association of Urology. Guidelines: prostate cancer. 2018. https://uroweb.org/guideline/prostate-cancer/?type=summary-of-changes . Accessed 6 May 2020.
Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. J Urol. 2020;203:706–12.
pubmed: 31642740
doi: 10.1097/JU.0000000000000617
Bosaily AES, Frangou E, Ahmed HU, Emberton M, Punwani E, Kaplan R, et al. Additional value of dynamic contrast-enhanced sequences in multiparametric prostate magnetic resonance imaging: data from the PROMIS study. Eur Urol. 2020. https://doi.org/10.1016/j.eururo.2020.03.002 .
Zawaideh JP, Sala E, Shaida N, Koo B, Warren AY, Carmisciano L, et al. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice. Eur Radiol. 2020. https://doi.org/10.1007/s00330-020-06782-0 .
Cosma I, Tennstedt-Schenk C, Winzler S, Psychogios MN, Pfeil A, Teichgraeber U, et al. The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: a diagnostic accuracy study. PLoS ONE. 2019;14:e0227031. https://doi.org/10.1371/journal.pone.0227031 .
doi: 10.1371/journal.pone.0227031
pubmed: 31869380
pmcid: 6927639
de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol. 2014;202:343–51.
doi: 10.2214/AJR.13.11046
Tan CH, Hobbs BP, Wei W, Kundra V. Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. Am J Roentgenol. 2016;204:W439–48.
doi: 10.2214/AJR.14.13373
Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup KC. et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naïve men: the biparametric MRI for detection of prostate cancer (BIDOC) study. JAMA Netw Open. 2019;1:e180219. https://doi.org/10.1001/jamanetworkopen.2018.0219 .
doi: 10.1001/jamanetworkopen.2018.0219
American College of Radiology. ACR Committee on Drugs and Contrast Media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf . Accessed 6 May 2020.
Niu XK, Chen XH, Chen ZF, Chen L, Li J, Peng T. Diagnostic performance of biparametric MRI for detection of prostate cancer: a systematic review and meta-analysis.Am J Roentgenol. 2018;211:369–78.
doi: 10.2214/AJR.17.18946
Moher D, Liberati A, Tetzlaff J, Altman DG.PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097 .
doi: 10.1371/journal.pmed.1000097
pubmed: 19621072
pmcid: 2707599
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
pubmed: 22007046
doi: 10.7326/0003-4819-155-8-201110180-00009
Leeflang MM, Deeks JJ, Takwoingi Y, Macaskill P. Cochrane diagnostic test accuracy reviews. Syst Rev. 2013;2:82.
pubmed: 24099098
pmcid: 3851548
doi: 10.1186/2046-4053-2-82
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid-Based Ment Health. 2019;22:153–60.
pubmed: 31563865
doi: 10.1136/ebmental-2019-300117
Shimofusa R, Fujimoto H, Akamata H, Motoori K, Yamamoto S, Ueda T, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr. 2005;29:149–53.
pubmed: 15772529
doi: 10.1097/01.rct.0000156396.13522.f2
Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging. 2007;25:146–62.
pubmed: 17139633
doi: 10.1002/jmri.20793
Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan M, Zerbib M, et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis. 2011;14:232–7.
pubmed: 21423266
doi: 10.1038/pcan.2011.9
Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology. 2011;259:775–84.
pubmed: 21436085
pmcid: 3099046
doi: 10.1148/radiol.11102066
Vilanova JC, Barceló-Vidal C, Comet J, Boada M, Barcelo J, Ferrer J, et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate specific antigen ratio in the detection of prostate cancer. Am J Roentgenol. 2011;196:W715–22.
doi: 10.2214/AJR.10.5700
Jung SI, Donati OF, Vargas HA, Goldman D, Hricak H, Akin O. Transition zone prostate cancer: incremental value of diffusion-weighted endorectal MR imaging in tumor detection and assessment of aggressiveness. Radiology. 2013;269:493–503.
pubmed: 23878284
doi: 10.1148/radiol.13130029
Lawrence EM, Tang SY, Barrett T, Koo B, Goldman DA, Warren AY, et al. Prostate cancer: performance characteristics of combined T2W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion. Eur Radio. 2014;24:1497–1505.
doi: 10.1007/s00330-014-3159-0
Thestrup KC, Logager V, Baslev I, Møller JM, Hansen RH, Thomsen HS. Biparametric versus multiparametric MRI in the diagnosis of prostate cancer. Acta Radio Open. 2016;5:2058460116663046.
Barth BK, De Visschere PJ, Cornelius A, Nicolau C, Vargas HA, Eberli D, et al. Detection of clinically significant prostate cancer: short dual-pulse sequence versus standard multiparametric MR imaging—a multireader study. Radiology. 2017;284:725–36.
pubmed: 28346073
doi: 10.1148/radiol.2017162020
Mussi TC, Martins T, Garcia RG, Filippi RZ, Lemos GC, Baroni RH. Are dynamic contrast-enhanced images necessary for prostate cancer detection on multiparametric magnetic resonance imaging? Clin Genitourin Cancer. 2017;15:e447–54.
pubmed: 27856204
doi: 10.1016/j.clgc.2016.10.001
Scialpi M, Prosperi E, D’Andrea A, Martorana E, Malaspina C, Palumbo B, et al. Biparametric versus multiparametric MRI with non-endorectal coil at 3T in the detection and localization of prostate cancer. Anticancer Res. 2017;37:1263–71.
pubmed: 28314291
doi: 10.21873/anticanres.11443
Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heindenreich A, Schrading S. Abbreviated biparametric prostate MR Imaging in men with elevated prostate-specific antigen. Radiology. 2017;285:493–505.
pubmed: 28727544
doi: 10.1148/radiol.2017170129
Lee SJ, Oh YT, Jung DC, Cho NH, Choi YD, Park SY. Combined analysis of biparametric MRI and prostate-specific antigen density: role in the prebiopsy diagnosis of Gleason Score 7 or greater prostate cancer. Am J Roentgenol. 2018;211:W166–72.
doi: 10.2214/AJR.17.19253
Kim SH, Choi MS, Kim MJ, Kim YH, Cho SH. Validation of prostate imaging reporting and data system version 2 using an MRI-ultrasound fusion biopsy in prostate cancer diagnosis. Am J Roentgenol. 2017;209:800–5.
doi: 10.2214/AJR.16.17629
Choi MH, Lee YJ, Jung SE, Rha SE, Byun JY. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels. Clin Radio. 2018;73:810–7.
doi: 10.1016/j.crad.2018.05.007
Obmann VC, Pahwa S, Tabayayong W, Jiang Y, O’Connor G, Dastmalchian S, et al. Diagnostic accuracy of a rapid biparametric MRI protocol for detection of histologically proven prostate cancer. Urology. 2018;122:133–8.
pubmed: 30201301
doi: 10.1016/j.urology.2018.08.032
Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT. et al. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional trial. PLoS Med. 2019;16:e1002813. https://doi.org/10.1371/journal.pmed.1002813 .
doi: 10.1371/journal.pmed.1002813
pubmed: 31158230
pmcid: 6546206
Van der Leest M, Israël B, Cornel EB, Zámecnik P, Schoots IO, van der Lelij H, et al. High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naïve men: the next step in magnetic resonance imaging accessibility. Eur Urol. 2019;76:574–81.
pubmed: 31167748
doi: 10.1016/j.eururo.2019.05.029
Gatti M, Faletti R, Calleris G, Giglio J, Berzovini C, Gentile F, et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radio (NY). 2019;44:1883–93.
doi: 10.1007/s00261-019-01934-3
Choi MH, Kim CK, Lee YJ, Jung SE. Prebiopsy biparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2: a multicenter study. Am J Roentgenol. 2019;212:839–46.
doi: 10.2214/AJR.18.20498
Junker D, Steinkohl F, Fritz V, Bektic J, Tokas T, Aigner F, et al. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol. 2019;37:691–9.
pubmed: 30078170
doi: 10.1007/s00345-018-2428-y
Haider MA, van der Kwast TH, Tanguay J, Evans A, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol. 2007;189:323–8.
doi: 10.2214/AJR.07.2211
Morgan VA, Kyriazi S, Ashley SE, DeSouza NM. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta Radio. 2007;48:695–703.
doi: 10.1080/02841850701349257
Yoshimitsu K, Kiyoshima K, Irie H, Tajima T, Asayama Y, Kirakawa M, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging. 2008;27:132–9.
pubmed: 18050334
doi: 10.1002/jmri.21181
Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radio. 2008;49:1207–13.
doi: 10.1080/02841850802508959
Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection: a multireader study. Radiology. 2009;250:145–51.
pubmed: 19017927
doi: 10.1148/radiol.2501080207
Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Sugunuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging. 2010;31:625–31.
pubmed: 20187206
doi: 10.1002/jmri.22075
Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding—multiparametric MR imaging for detection and biopsy planning. Radiology. 2011;259:162–72.
pubmed: 21233291
doi: 10.1148/radiol.10101251
Katahira K, Takahara T, Kwee TC, Oda S, Suzuki Y, Morishita S, et al. Ultra-high- b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radio. 2011;21:188–96.
doi: 10.1007/s00330-010-1883-7
Naiki T, Okamura T, Nagata D, Mori Y, Kawai N, Ogawa K, et al. Preoperative prediction of neurovascular bundle involvement of localized prostate cancer by combined T2 and diffusion-weighted imaging of magnetic resonance imaging, number of positive biopsy cores, and Gleason score. Asian Pac J Cancer Prev. 2011;12:909–13.
pubmed: 21790224
Rosenkrantz AB, Mannelli L, Kong X, Niver BE, Berkman DS, Babb JS, et al. Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging. 2011;34:95–100.
pubmed: 21698707
doi: 10.1002/jmri.22598
Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, Oh YW, et al. Detectability of low and intermediate of high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Urol. 2012;22:1812–19.
Rinaldi D, Fiocchi F, Ligabue G, Bianchi G, Torricelli P. Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation. Radio Med (Torino). 2012;117:1429–40.
doi: 10.1007/s11547-012-0832-8
Ueno Y, Takahashi S, Kitajima K, Kimura T, Aoki I, Kawakami H, et al. Computed diffusion-weighted imaging using 3-T magnetic resonance imaging for prostate cancer diagnosis. Eur Radio. 2013;23:3509–16.
doi: 10.1007/s00330-013-2958-z
Ueno Y, Kitajima K, Sugimura K, Kawakami F, Miyake H, Obara M, et al. Ultra-high b-value diffusion-weighted MRI for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging. 2013;38:154–60.
pubmed: 23292979
doi: 10.1002/jmri.23953
Abdel Maboud NM, Elsaid HH, Aboubeih EA. The role of diffusion-weighted MRI in evaluation of prostate cancer. Egypt J Radio Nucl Med. 2014;45:231–6.
doi: 10.1016/j.ejrnm.2013.11.010
Kitamura K, Muto S, Yokota I, Hoshimoto K, Kaminaga T, Noguchi T, et al. Feasibility of multiparametric prostate magnetic resonance imaging in the detection of cancer distribution: histopathological correlation with prostatectomy specimens. Prostate Int. 2014;2:188–95.
pubmed: 25599075
pmcid: 4286731
doi: 10.12954/PI.14067
Brock M, Roghmann F, Sonntag C, Sommerer F, Tian Z, Löppenberg B, et al. Fusion of magnetic resonance imaging and real-time elastography to visualize prostate cancer: a prospective analysis using whole mount sections after radical prostatectomy. Ultraschall Med. 2015;36:355–61.
pubmed: 24854132
Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, et al. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int. 2015;115:381–8.
pubmed: 24447678
doi: 10.1111/bju.12639
Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, et al. Combined biparametric prostate magnetic resonance imaging and prostate-specific antigen in the detection of prostate cancer: a validation study in a biopsy-naive patient population. Urology. 2016;88:125–34.
pubmed: 26680244
doi: 10.1016/j.urology.2015.09.035
Yağci AB, Ozari N, Aybek Z, Düzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Inter Radio. 2011;17:130–4.
Stanzione A, Imbriaco M, Cocozza S, Fusco F, Rusconi G, Nappi C, et al. Biparametric 3T magnetic resonance imaging for prostatic cancer detection in a biopsy-naïve patient population: a further improvement of PI-RADS v2? Eur J Radio. 2016;85:2269–74.
doi: 10.1016/j.ejrad.2016.10.009
Wang X, Wang JY, Li CM, Zhang YQ, Wang JL, Wan B, et al. Evaluation of the prostate imaging reporting and data system for magnetic resonance imaging diagnosis of prostate cancer in patients with prostate-specific antigen <20 ng/ml. Chin Med J (Engl). 2016;129:1432–8.
doi: 10.4103/0366-6999.183419
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374–83.
pubmed: 19276453
pmcid: 2720697
doi: 10.1093/jnci/djp001
Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Screening intervention on prostate cancer mortality, the CAP randomized clinical trial. JAMA. 2018;319:883–95.
pubmed: 29509864
pmcid: 5885905
doi: 10.1001/jama.2018.0154
Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov V, Hussey SK, et al. Annual report to the nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801–14.
pubmed: 29786851
doi: 10.1002/cncr.31549
Scott S, Samaratunga H, Chabert C, Breckenbridge M, Gianduzzo T. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis. BJU Int. 2015;116(Suppl 3):26–30.
pubmed: 26260531
doi: 10.1111/bju.13165
Jiang X, Zhu S, Feng G, Zhang Z, Li C, Li H, et al. Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis. Eur Urol. 2013;63:1031–9.
pubmed: 23414775
doi: 10.1016/j.eururo.2013.01.035
Altok M, Kim B, Patel BB, Shih YCT, Ward JF, McRae SE, et al. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018;21:524–32.
pubmed: 29988098
doi: 10.1038/s41391-018-0056-7
Giannarini G, Girometti R, Crestani A, Rossanese M, Calandriello M, Cereser L, et al. A prospective accuracy study of prostate imaging reporting and data system version 2 on multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer with whole-mount pathology. Urology. 2019;123:191–7.
pubmed: 30273613
doi: 10.1016/j.urology.2018.07.067
Elwenspoek MMC, Sheppard AL, McInnes MDF, Merriel SWD, Rowe EWJ, Bryant RJ. et al. Comparison of multiparametric magnetic resonance imaging and targeted biopsy with systematic biopsy alone for the diagnosis of prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e198427. https://doi.org/10.1001/jamanetworkopen.2019.8427 .
doi: 10.1001/jamanetworkopen.2019.8427
pubmed: 31390032
pmcid: 6686781
Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, et al. Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the prostate MR imaging study (PROMIS). Eur Urol. 2018;73:23–30.
pubmed: 28935163
pmcid: 5718727
doi: 10.1016/j.eururo.2017.08.018
Hegde J, Mulkern R, Pahych L, Fennessy FM, Fedorov A, Maier SE, et al. Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and the performance in detecting and localizing prostate cancer. J Magn Reson Imaging. 2013;37:1035–54.
pubmed: 23606141
pmcid: 3741996
doi: 10.1002/jmri.23860
Torricelli P, Cinquantini F, Ligabue G, Bianchi G, Sighinolfi P, Romagnoli R. Comparative evaluation between external phased array coil at 3 T and endorectal coil at 1.5 T: preliminary results. J Comput Assist Tomogr. 2006;30:355–61.
pubmed: 16778606
doi: 10.1097/00004728-200605000-00002
Barth BK, Rupp NJ, Cornelius A, Nanz D, Grobholz R, Schmidtpeter M, et al. Diagnostic accuracy of a MR protocol acquired with and without endorectal coil for detection of prostate cancer: a multicenter study. Curr Urol. 2019;12:88–96.
pubmed: 31114466
pmcid: 6504800
doi: 10.1159/000489425
Fütterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, Hulsbergen-Van de Kaa CA, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radio. 2007;17:1055–65.
doi: 10.1007/s00330-006-0418-8
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging-reporting and data system: 2015, Version 2. Eur Urol. 2016;69:16–40.
pubmed: 26427566
doi: 10.1016/j.eururo.2015.08.052
Punwani S, Emberton M, Walkden M, Sohaib A, Freeman A, Ahmed H, et al. Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. Br J Radio. 2012;85:720–8.
doi: 10.1259/bjr/61380797
Wu LM, Xu JR, Gu HY, Hua J, Zhu J, Chen J, et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radio). 2013;25:252–64.
doi: 10.1016/j.clon.2012.11.010
Shim S, Kim SJ, Lee J. Diagnostic test accuracy: application and practice using R software. Epidemiol Health. 2019;41:e2019007.
pubmed: 30999739
pmcid: 6545496
doi: 10.4178/epih.e2019007